Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1653001 | 0.83 | GPR35 (0.43) | ALDH1A1GPR35POLBTDP1L3MBTL1 | |
| SCHEMBL29653751 | 0.80 | ALDH1A1 (0.48) | ALDH1A1SLC7A5MMP2POLBSENP8 | |
| SCHEMBL30451723 | 0.80 | ALDH1A1 (0.48) | ALDH1A1SLC7A5MMP2POLBSENP8 | |
| SCHEMBL27781696 | 0.80 | ALDH1A1 (0.48) | ALDH1A1SLC7A5MMP2POLBSENP8 | |
| SCHEMBL1653846 | 0.79 | GPR35 (0.39) | ALDH1A1GPR35POLBL3MBTL1 | |
| SCHEMBL11220084 | 0.78 | MMP2 (0.41) | ALDH1A1MMP2GPR35L3MBTL1 | |
| SCHEMBL3031094 | 0.78 | MMP2 (0.41) | ALDH1A1MMP2GPR35L3MBTL1 | |
| SCHEMBL1653798 | 0.77 | GPR35 (0.45) | ALDH1A1GPR35POLBTDP1L3MBTL1 | |
| SCHEMBL7865835 | 0.77 | KDM4A (0.47) | ALDH1A1SLC7A5MMP2HDAC8 | |
| SCHEMBL28393254 | 0.77 | KDM4A (0.47) | ALDH1A1SLC7A5MMP2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092557-A1 | Neuraminidase Inhibitors And Compositions And Methods Related Thereto | INFLUMEDIX INC. (US) | 2011-04-21 | — | — | US | claimed |
| US-20110092557-A1 | Neuraminidase Inhibitors And Compositions And Methods Related Thereto | INFLUMEDIX INC. (US) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092557-A1 | Neuraminidase Inhibitors And Compositions And Methods Related Thereto | NEU1, DAO, NEU3 | ALDH1A1 2018/4885SLC7A5 1008/4885MMP2 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.